Track Schrodinger, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Schrodinger, Inc. SDGR · Stock Open Schrodinger, Inc. in new tab

29.53 USD
EPS
-0.79
P/B
7.67
ROE
-19.02
Beta
1.65
Target Price
33.57 USD
Schrodinger, Inc. logo

Schrodinger, Inc.

🧾 Earnings Recap – Q3 2026

Schrödinger’s shares rose 0.9%, a roughly flat reaction. The company raised full-year ACV and drug discovery revenue guidance, while ACV growth excluding contribution ACV was 24%; the call also highlighted ongoing customer evaluations for newer products.

  • ACV grew 17%, or 24% excluding contribution ACV, driven by adoption in large pharma, new products, biotech and materials customers, and customer additions.
  • Management raised full-year guidance for ACV and drug discovery revenue, citing third-quarter performance.
  • Bunsen handled approximately 80% of the company’s high-throughput calculations on its internal compute cluster; multiple customers are evaluating it.
  • Predictive toxicology evaluations are progressing, and the platform can now assess more than 80 potential off-target proteins computationally.
  • Schrödinger received a milestone payment tied to progress in Structured Therapeutics’ oral amylin program; Takeda’s application for zasocitinib was accepted for priority review.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 24, 2027
EPS-0.79
Book Value4.02
Price to Book7.67
Debt/Equity34.66
% Insiders2.992%
Growth
Revenue Growth0.19%
Estimates
Forward P/E-25.50
Forward EPS-1.21
Target Mean Price33.57

DCF valuation

Model fair value for Schrodinger, Inc. (SDGR)
Result
Sign in to run the valuation for SDGR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus Buy · mean target 33.57 USD (low 29.00, high 37.00) · as of 13 Nov 2026
Low 29.00
Mean 33.57
High 37.00
Price 29.53
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Schrodinger, Inc. Logo Schrodinger, Inc. Analysis (SDGR)

United States Health Care Official Website Stock

Is Schrodinger, Inc. a good investment? Schrodinger, Inc. (SDGR) is currently trading at 29.53 USD. Market analysts have a consensus price target of 33.57 USD. This suggests a potential upside from current levels.

Earnings Schedule: Schrodinger, Inc. is expected to release its next earnings report on Feb. 24, 2027. The market consensus estimate for Forward EPS is -1.21.

Investor FAQ

Does Schrodinger, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Schrodinger, Inc.?

Schrodinger, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 24, 2027. The company currently has a trailing EPS of -0.79.

Company Profile

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Exchange Ticker
NMS (United States) SDGR
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion